PainReform Ltd.

PainReform Ltd.

$5.3
-5.86 (-52.51%)
NASDAQ Capital Market
USD, IL
Drug Manufacturers - Specialty & Generic

PRFX Price Chart

Basic
Market Cap$1.81M
Price$5.3
52 Week Range0.432-20.16
Beta0.56
Margins
Gross Profit Margin-166659512925868.63%
Operating Profit Margin-174757204553831520.00%
Net Profit Margin-173257268937499424.00%
Valuation (TTM)
P/E Ratio-0.17
Price to Sales Ratio59670281832911.91
Price to Book Ratio-1.50
PEG Ratio0.18

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

Full-Time Employees

7

IPO Date

2020-09-01T00:00:00.000Z

Description

PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.

Phone

972 3 717 7050

Address

65 Yigal Alon Street, Tel Aviv, 6745442, IL

CIK

0001801834